Shopping Cart 0
Cart Subtotal
AED 0

Janssen Pharmaceutica NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Janssen Pharmaceutica NV (Janssen Pharmaceutica), a subsidiary of Johnson & Johnson is a drug development and manufacturing company that discover, develop, and produce medicines and therapeutic solutions. The company provides products such as human medicine products, veterinary products, and preservation and material protection products. It develops products for the disease areas such as mental disorders, neurological problems, infectious diseases, immunological disorders, cancer, and cardiovascular and metabolic conditions. The company also offers education, services, and support programs. It operates in Beerse, Geel, Olen, Merksem, Diegem, La Louviere, and Courcelles. Janssen Pharmaceutica is headquartered in Antwerp, Belgium.

Janssen Pharmaceutica NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 12

Partnerships 14

Janssen Pharma to Enter into Agreement with Pharmstandard 14

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 15

Intrexon Enters into Research Agreement with Janssen Pharma 16

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 17

Licensing Agreements 18

Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 18

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 19

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 21

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 22

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 23

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 25

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 26

Kura Oncology Amends Licensing Agreement with Janssen Pharma 28

Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 30

BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 31

Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 32

NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 33

Asset Transactions 34

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 34

Kramer Labs Acquires Nizoral from Janssen Pharma 35

Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 36

Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 37

Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 38

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39

Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For USD 357 Million 40

Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 41

Janssen Pharmaceutica NV-Key Competitors 42

Janssen Pharmaceutica NV-Key Employees 43

Janssen Pharmaceutica NV-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 45

Other Significant Developments 45

Jul 25, 2018: Launch of Single Cell Accelerator drives VIB to forefront of single cell research 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Key Facts 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 12

Janssen Pharma to Enter into Agreement with Pharmstandard 14

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 15

Intrexon Enters into Research Agreement with Janssen Pharma 16

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 17

Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 18

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 19

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 21

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 22

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 23

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 25

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 26

Kura Oncology Amends Licensing Agreement with Janssen Pharma 28

Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 30

BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 31

Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 32

NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 33

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 34

Kramer Labs Acquires Nizoral from Janssen Pharma 35

Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 36

Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 37

Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 38

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39

Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For USD 357 Million 40

Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 41

Janssen Pharmaceutica NV, Key Competitors 42

Janssen Pharmaceutica NV, Key Employees 43

Janssen Pharmaceutica NV, Other Locations 44

Janssen Pharmaceutica NV, Subsidiaries 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Janssen Pharmaceutica NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Janssen Pharmaceutica NV (Janssen Pharmaceutica), a subsidiary of Johnson & Johnson is a drug development and manufacturing company that discover, develop, and produce medicines and therapeutic solutions. The company provides products such as human medicine products, veterinary products, and preservation and material protection products. It develops products for the disease areas such as mental disorders, neurological problems, infectious diseases, immunological disorders, cancer, and cardiovascular and metabolic conditions. The company also offers education, services, and support programs. It operates in Beerse, Geel, Olen, Merksem, Diegem, La Louviere, and Courcelles. Janssen Pharmaceutica is headquartered in Antwerp, Belgium.

Janssen Pharmaceutica NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 12

Partnerships 14

Janssen Pharma to Enter into Agreement with Pharmstandard 14

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 15

Intrexon Enters into Research Agreement with Janssen Pharma 16

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 17

Licensing Agreements 18

Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 18

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 19

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 21

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 22

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 23

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 25

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 26

Kura Oncology Amends Licensing Agreement with Janssen Pharma 28

Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 30

BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 31

Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 32

NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 33

Asset Transactions 34

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 34

Kramer Labs Acquires Nizoral from Janssen Pharma 35

Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 36

Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 37

Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 38

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39

Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For USD 357 Million 40

Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 41

Janssen Pharmaceutica NV-Key Competitors 42

Janssen Pharmaceutica NV-Key Employees 43

Janssen Pharmaceutica NV-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 45

Other Significant Developments 45

Jul 25, 2018: Launch of Single Cell Accelerator drives VIB to forefront of single cell research 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Key Facts 2

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Janssen Pharmaceutica NV, Deals By Therapy Area, 2012 to YTD 2018 8

Janssen Pharmaceutica NV, Medical Devices Deals, 2012 to YTD 2018 9

Janssen Pharmaceutica NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For USD 152 Million 12

Janssen Pharma to Enter into Agreement with Pharmstandard 14

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 15

Intrexon Enters into Research Agreement with Janssen Pharma 16

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 17

Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland 18

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 19

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 21

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 22

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 23

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 25

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 26

Kura Oncology Amends Licensing Agreement with Janssen Pharma 28

Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 30

BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 31

Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 32

NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 33

Stada Arzneimittel Acquires Nizoral from Janssen Pharma 34

Kramer Labs Acquires Nizoral from Janssen Pharma 35

Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million 36

Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 37

Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 38

Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39

Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For USD 357 Million 40

Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 41

Janssen Pharmaceutica NV, Key Competitors 42

Janssen Pharmaceutica NV, Key Employees 43

Janssen Pharmaceutica NV, Other Locations 44

Janssen Pharmaceutica NV, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Janssen Pharmaceutica NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.